Welcome to the year-long celebration.

The FDA has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody being investigated for the treatment of patients with early Alzheimer disease.

Check out the positive topline results from a phase 2 dose finding trial evaluating N-methyl amisulpride (LB-102) in adult patients with acute schizophrenia.

Panelists discuss how breaking the stigma around postpartum depression requires both healthcare providers and society to normalize open conversations about maternal mental health, while encouraging mothers to seek support without shame or judgment.

There is no accurate profile of who will become a school shooter, so mental health clinicians should react as they would with any patient threatening violence: inquire, gain collateral data, assess, and respond.

Bipolar I disorder (BD-I) can be difficult to diagnose and treat due to overlapping symptoms and stigma. What can clinicians utilize to help manage BD-I for better long-term outcomes?

Nuclear war capability: why we should be worried psychiatrically.

Do you want to be featured in a future Special Report? Check out our January theme!

How can psychiatric clinicians ensure their practices are accessible to patients with disabilities?

Psychiatric Times: Supporting clinicians, promoting conversations, and improving patient care over the past 40 years.

How much fear is too much?

How will the definition of assisted death (AD) as medical care impact its utilization?

Panelists discuss how real patients navigate the complex journey of seeking and receiving postpartum depression care, from overcoming stigma and recognizing symptoms to finding appropriate healthcare providers and accessing treatment while managing new motherhood responsibilities.

"Things fall apart; the centre cannot hold; Mere anarchy is loosed upon the world..."

Essay contest winners will be announced on January 6th.

A panelist discusses how clinicians implement posttraumatic stress disorder (PTSD) treatments through a carefully structured approach that begins with establishing safety and stabilization, progresses through trauma processing using evidence-based interventions, and concludes with integration and relapse prevention strategies, all while maintaining therapeutic alliance and adjusting treatment intensity based on patient response.

A panelist discusses how treatment options for posttraumatic stress disorder (PTSD) encompass a wide range of evidence-based approaches, including trauma-focused cognitive behavioral therapy, medication management, exposure therapy, and complementary interventions such as mindfulness and group support, which can be tailored to meet individual patient needs and circumstances.

Panelists discuss how the recent FDA-approved treatments for postpartum depression (PPD), including zuranolone and brexanolone , offer new options for rapid symptom relief and improve the management of severe PPD cases.

The final installment in this journal on ketamine.

Navacaprant for the treatment of major depressive disorder has failed in the phase 3 KOASTAL-1 trial.

A psychiatrist reflects on the New Year and its potential...

We asked our contributors at the 63rd meeting of the American College of Neuropsychopharmacology what they are excited about from 2024 and what they are looking forward to in 2025. Here's what they said.

How do your fellow clinicians feel about the holidays? Are they feeling the effects of burnout heading into 2025? Find out here.

Let's review the Special Reports of 2024!

Who would be the optimal candidate to receive focused ultrasound to treat obsessive-compulsive disorder?